These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 20843305)
1. Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation. Pradhan M; Risberg BA; Tropé CG; van de Rijn M; Gilks CB; Lee CH BMC Cancer; 2010 Sep; 10():493. PubMed ID: 20843305 [TBL] [Abstract][Full Text] [Related]
2. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854 [TBL] [Abstract][Full Text] [Related]
3. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. Lee CH; Subramanian S; Beck AH; Espinosa I; Senz J; Zhu SX; Huntsman D; van de Rijn M; Gilks CB PLoS One; 2009 Oct; 4(10):e7314. PubMed ID: 19798417 [TBL] [Abstract][Full Text] [Related]
5. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084 [TBL] [Abstract][Full Text] [Related]
6. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976 [TBL] [Abstract][Full Text] [Related]
7. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585 [TBL] [Abstract][Full Text] [Related]
8. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor. Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687 [TBL] [Abstract][Full Text] [Related]
9. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas. Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802 [TBL] [Abstract][Full Text] [Related]
10. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. Press JZ; De Luca A; Boyd N; Young S; Troussard A; Ridge Y; Kaurah P; Kalloger SE; Blood KA; Smith M; Spellman PT; Wang Y; Miller DM; Horsman D; Faham M; Gilks CB; Gray J; Huntsman DG BMC Cancer; 2008 Jan; 8():17. PubMed ID: 18208621 [TBL] [Abstract][Full Text] [Related]
12. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers. Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626 [TBL] [Abstract][Full Text] [Related]
13. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471 [TBL] [Abstract][Full Text] [Related]
14. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700 [TBL] [Abstract][Full Text] [Related]
16. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Moschetta M; George A; Kaye SB; Banerjee S Ann Oncol; 2016 Aug; 27(8):1449-55. PubMed ID: 27037296 [TBL] [Abstract][Full Text] [Related]
17. A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer. Evans DGR; van Veen EM; Byers HJ; Wallace AJ; Ellingford JM; Beaman G; Santoyo-Lopez J; Aitman TJ; Eccles DM; Lalloo FI; Smith MJ; Newman WG Am J Hum Genet; 2018 Aug; 103(2):213-220. PubMed ID: 30075112 [TBL] [Abstract][Full Text] [Related]
18. Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency. Reyes MC; Arnold AG; Kauff ND; Levine DA; Soslow RA Mod Pathol; 2014 Oct; 27(10):1405-11. PubMed ID: 24577588 [TBL] [Abstract][Full Text] [Related]
19. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer]. Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312 [No Abstract] [Full Text] [Related]
20. The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. Meisel JL; Hyman DM; Garg K; Zhou Q; Dao F; Bisogna M; Gao J; Schultz ND; Grisham RN; Phillips M; Iasonos A; Kauff ND; Levine DA; Soslow RA; Spriggs DR Ann Oncol; 2014 Dec; 25(12):2372-2378. PubMed ID: 25281711 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]